Rapid Development and Initial Preclinical Evaluation of an Effective Candidate Vaccine against SARS-CoV-2
The current pandemic caused by SARS-CoV-2 is a threat not only to global health but also to the economy since it is dramatically affecting the socioeconomic layers of societies around the planet. Thus, it will be critically important to advance in the production of an effective vaccine, which will be crucial for building up sufficient population-based immunity to efficiently curb the pandemic. While SARS-CoV-2 can infect everyone at all ages, it is mainly the elderly population that is most at risk of a fatal outcome. Elderly persons are charecterized by a declining immune function, known a...
Functional characterization of COVID-19 patient gut microbiome
While COVID-19 is mainly considered an airway and lung disease, up to 79% of patients present with gastrointestinal symptoms and recent studies report on the presence of SARS-CoV-2 viral RNA and particles in stools of infected patients, suggesting that the gastrointestinal (GI) tract may have a more important role in disease pathology or transmission than previously thought. The GI tract is also the site of the dense and diverse microbiome, which has the ability to regulate intestinal and systemic immunity through the conversion of dietary nutrients into bioactive metabolites. Consequently,...
COVID-19 and Neurturin
SARS-Cov-2 is a coronavirus is at the origin of the current COVID-19 pandemic, which poses a global and significant threat to public health worldwide. Although several treatment modalities have been evaluated, none has allowed a therapeutic breakthrough until now. New treatment modalities are therefore urgently needed. We have previously described that neurturin, a member of the glial cell line-derived neurotrophic factor family, expressed not only as a growth factor in the nervous system but also the immune system, displays clear anti-inflammatory properties in mouse asthma models. Indeed,...